Zhang Financial LLC trimmed its stake in shares of UBS Group AG (NYSE:UBS – Free Report) by 77.8% in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 8,927 shares of the bank’s stock after selling 31,284 shares during the quarter. Zhang Financial LLC’s holdings in UBS Group were worth $273,000 at the end of the most recent reporting period.
Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Kingsview Wealth Management LLC bought a new position in UBS Group during the fourth quarter worth $218,000. Jones Financial Companies Lllp boosted its position in shares of UBS Group by 142.4% in the fourth quarter. Jones Financial Companies Lllp now owns 22,023 shares of the bank’s stock valued at $668,000 after acquiring an additional 12,939 shares during the period. Allspring Global Investments Holdings LLC boosted its position in shares of UBS Group by 13.0% in the fourth quarter. Allspring Global Investments Holdings LLC now owns 42,753 shares of the bank’s stock valued at $1,307,000 after acquiring an additional 4,912 shares during the period. Steward Partners Investment Advisory LLC grew its stake in shares of UBS Group by 42.2% in the fourth quarter. Steward Partners Investment Advisory LLC now owns 2,989 shares of the bank’s stock valued at $91,000 after acquiring an additional 887 shares in the last quarter. Finally, Blair William & Co. IL grew its stake in shares of UBS Group by 11.5% in the fourth quarter. Blair William & Co. IL now owns 7,976 shares of the bank’s stock valued at $242,000 after acquiring an additional 823 shares in the last quarter.
UBS Group Trading Down 0.2%
UBS opened at $32.65 on Friday. UBS Group AG has a twelve month low of $25.75 and a twelve month high of $35.84. The company has a 50-day simple moving average of $30.76 and a 200 day simple moving average of $31.92. The company has a quick ratio of 1.05, a current ratio of 1.06 and a debt-to-equity ratio of 3.76. The stock has a market capitalization of $104.69 billion, a price-to-earnings ratio of 21.48 and a beta of 1.16.
Wall Street Analysts Forecast Growth
Several research firms recently commented on UBS. Jefferies Financial Group upgraded shares of UBS Group from a “hold” rating to a “buy” rating in a research note on Tuesday, June 3rd. Wedbush restated a “neutral” rating on shares of UBS Group in a research note on Tuesday, May 27th. Royal Bank of Canada restated an “outperform” rating on shares of UBS Group in a research note on Wednesday, May 21st. Keefe, Bruyette & Woods upgraded shares of UBS Group from a “moderate sell” rating to a “hold” rating in a research note on Thursday, April 17th. Finally, Morgan Stanley downgraded shares of UBS Group from an “overweight” rating to an “equal weight” rating in a research note on Thursday, February 20th. One investment analyst has rated the stock with a sell rating, four have issued a hold rating, five have given a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy”.
View Our Latest Report on UBS Group
About UBS Group
UBS Group AG provides financial advice and solutions to private, institutional, and corporate clients worldwide. It operates through five divisions: Global Wealth Management, Personal & Corporate Banking, Asset Management, Investment Bank, and Non-core and Legacy. The company offers investment advice, estate and wealth planning, investing, corporate and banking, and investment management, as well as mortgage, securities-based, and structured lending solutions.
Featured Articles
- Five stocks we like better than UBS Group
- How to trade using analyst ratings
- Ignore the Noise—Samsara Stock Is Still a Strong Buy
- 3 Fintech Stocks With Good 2021 Prospects
- 3 Stocks Set to Double—And There’s Still Time to Buy
- Are These Liquid Natural Gas Stocks Ready For An Upside Bounce?
- Analysts Can’t Get Enough of These Little-Known Biopharma Stocks
Receive News & Ratings for UBS Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for UBS Group and related companies with MarketBeat.com's FREE daily email newsletter.